“Malignant Pleural Mesothelioma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Mesothelioma Market.
The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Malignant Pleural Mesothelioma Pipeline Report:
Companies across the globe are diligently working toward developing novel Malignant Pleural Mesothelioma treatment therapies with a considerable amount of success over the years.
Malignant Pleural Mesothelioma companies working in the treatment market are Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, AstraZeneca, Merck & Co, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others, are developing therapies for the Malignant Pleural Mesothelioma treatment
Emerging Malignant Pleural Mesothelioma therapies in the different phases of clinical trials are- INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, Durvalumab, Pembrolizumab, MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), MTG201 + nivolumab, ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN, and others are expected to have a significant impact on the Malignant Pleural Mesothelioma market in the coming years.
In September 2024, The U.S. Food and Drug Administration (FDA) has approved the combination of first-line pembrolizumab (Keytruda), pemetrexed, and platinum chemotherapy for the treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The FDA’s decision was based on the outcomes of the open-label, phase 2/3 KEYNOTE-483 clinical trial, which involved 440 patients with unresectable advanced or metastatic MPM who had not previously received systemic therapy for advanced disease
In February 2024, RS Oncology (RSO), a clinical-stage biotechnology company focused on developing innovative therapies to treat mesothelioma and other diseases, today announced the successful administration of the first dose to a patient in the Phase 2 dose expansion phase of its multicenter study in the United Kingdom (MITOPE; NCT05278975).
Malignant Pleural Mesothelioma Overview
Malignant Pleural Mesothelioma (MPM) is a rare and aggressive cancer that primarily affects the pleura, the lining of the lungs. It is most commonly caused by exposure to asbestos, which leads to the growth of malignant cells in the pleural lining. Symptoms often include chest pain, difficulty breathing, and persistent cough. MPM has a poor prognosis due to its late-stage diagnosis, and treatment options typically involve chemotherapy, radiation, and surgery, although no cure currently exists.
Get a Free Sample PDF Report to know more about Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight
Emerging Malignant Pleural Mesothelioma Drugs Under Different Phases of Clinical Development Include:
INBRX-109: Inhibrx
NX-1607: Nurix Therapeutics
ATA2271: Atara Biotherapeutics
TC-510: TCR2 Therapeutics
RSO-021: RS Oncology
SAR-444245: Sanofi
Durvalumab: AstraZeneca
Pembrolizumab: Merck & Co
MesoPher: Amphera BV
Pegargiminase: Polaris Pharmaceuticals
Galinpepimut-S (Vaccine): Sellas Life Sciences Group
MTG201 + nivolumab: Momotaro-Gene
ZEPZELCA (lurbinectedin): PharmaMar
IMFINZI: AstraZeneca
ONCOS-102: Targovax
TC-210: TCR2 Therapeutics
TECENTRIQ Plus AVASTIN: Hoffmann-La Roche
Malignant Pleural Mesothelioma Route of Administration
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Malignant Pleural Mesothelioma Molecule Type
Malignant Pleural Mesothelioma Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Malignant Pleural Mesothelioma Pipeline Therapeutics Assessment
Malignant Pleural Mesothelioma Assessment by Product Type
Malignant Pleural Mesothelioma By Stage and Product Type
Malignant Pleural Mesothelioma Assessment by Route of Administration
Malignant Pleural Mesothelioma By Stage and Route of Administration
Malignant Pleural Mesothelioma Assessment by Molecule Type
Malignant Pleural Mesothelioma by Stage and Molecule Type
DelveInsight’s Malignant Pleural Mesothelioma Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Malignant Pleural Mesothelioma product details are provided in the report. Download the Malignant Pleural Mesothelioma pipeline report to learn more about the emerging Malignant Pleural Mesothelioma therapies
Some of the key companies in the Malignant Pleural Mesothelioma Therapeutics Market include:
Key companies developing therapies for Malignant Pleural Mesothelioma are – Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others.
Malignant Pleural Mesothelioma Pipeline Analysis:
The Malignant Pleural Mesothelioma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Mesothelioma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma Treatment.
Malignant Pleural Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Malignant Pleural Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Mesothelioma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Malignant Pleural Mesothelioma drugs and therapies
Malignant Pleural Mesothelioma Pipeline Market Drivers
Increased adoption of combination therapies are some of the important factors that are fueling the Malignant Pleural Mesothelioma Market.
Malignant Pleural Mesothelioma Pipeline Market Barriers
However, treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem, high Cost of Treatment and other factors are creating obstacles in the Malignant Pleural Mesothelioma Market growth.
Scope of Malignant Pleural Mesothelioma Pipeline Drug Insight
Coverage: Global
Key Malignant Pleural Mesothelioma Companies: Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, AstraZeneca, Merck & Co, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others
Key Malignant Pleural Mesothelioma Therapies: INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, Durvalumab, Pembrolizumab, MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), MTG201 + nivolumab, ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN, and others
Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers
Request for Sample PDF Report for Malignant Pleural Mesothelioma Pipeline Assessment and clinical trials
Table of Contents
1. Malignant Pleural Mesothelioma Report Introduction
2. Malignant Pleural Mesothelioma Executive Summary
3. Malignant Pleural Mesothelioma Overview
4. Malignant Pleural Mesothelioma- Analytical Perspective In-depth Commercial Assessment
5. Malignant Pleural Mesothelioma Pipeline Therapeutics
6. Malignant Pleural Mesothelioma Late Stage Products (Phase II/III)
7. Malignant Pleural Mesothelioma Mid Stage Products (Phase II)
8. Malignant Pleural Mesothelioma Early Stage Products (Phase I)
9. Malignant Pleural Mesothelioma Preclinical Stage Products
10. Malignant Pleural Mesothelioma Therapeutics Assessment
11. Malignant Pleural Mesothelioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Malignant Pleural Mesothelioma Key Companies
14. Malignant Pleural Mesothelioma Key Products
15. Malignant Pleural Mesothelioma Unmet Needs
16 . Malignant Pleural Mesothelioma Market Drivers and Barriers
17. Malignant Pleural Mesothelioma Future Perspectives and Conclusion
18. Malignant Pleural Mesothelioma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
